View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
July 24, 2019updated 12 Jul 2022 12:28pm

Merck reports positive data from islatravir’s HIV trial

Merck has reported positive findings from a Phase I clinical trial conducted in healthy volunteers to study extended administration of its HIV drug islatravir using a sub-dermal drug-eluting implant.

Merck has reported positive findings from a Phase I clinical trial conducted in healthy volunteers to study extended administration of its HIV drug islatravir using a sub-dermal drug-eluting implant.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Islatravir is an investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) intended for combination with other antiretrovirals to treat HIV-1 infection.

Various formulations of the drug are also being developed as a monotherapy for potential pre-exposure prophylaxis (PrEP) of HIV-1 infection.

Merck Research Laboratories chief medical officer and global clinical development senior vice-president and head Dr Roy Baynes said: “At Merck, we recognise multiple options are needed to address the needs of individuals at risk of HIV-1, and we are committed to investigating those options.

“Through the application of our established expertise in drug delivery, we are seeking to capture the potential of islatravir for HIV-1 PrEP.”

The Phase I trial was designed to assess the safety and pharmacokinetics of a polymer drug-eluting implant that delivered Merck’s therapeutic in healthy adult participants.

Subjects received a sub-dermal implant in the upper arm of their non-dominant hand. They were given 62mg or 54mg dose of islatravir or placebo.

The implant was removed after 12 weeks and volunteers were monitored for an additional four weeks.

Findings showed that both doses of the therapeutic were above calculated pharmacokinetic thresholds at 12 weeks.

Further modelling revealed that the implant with 62mg islatravir led to levels that were well above the threshold at 12 months. This is believed to indicate the potential for once-yearly PrEP.

Merck added that the data suggests intracellular concentrations can be managed by adjusting the drug load in the implant.

No participants discontinued the study due to adverse events (AE) and did not report any severe implant-related AEs. All subjects experienced at least one AE and all drug-related AEs were observed to be mild or moderately severe.

In addition, pooled analysis of vital signs, ECG parameters, and safety laboratory studies revealed no clinically significant differences between the investigational drug and placebo groups.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena